|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results are consistent with LRIG1 being a tumour suppressor gene in humans.
|
12234026 |
2002 |
|
Carcinogenesis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
However, further studies are justified to elucidate the explicit role of LRIG1 as a negative regulator of oncogenesis.
|
12234026 |
2002 |
|
Epithelial hyperplasia of skin
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia.
|
12067728 |
2002 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In all, 31 renal cell carcinomas (RCCs) were examined for expression of the potential tumour suppressor LRIG1 (formerly Lig-1) and the epidermal growth factor receptor (EGFR).
|
14520461 |
2003 |
|
Carcinogenesis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Further studies are justified to elucidate the explicit role of LRIG1 in the oncogenesis of RCC.
|
14520461 |
2003 |
|
Renal Cell Carcinoma
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
Further studies are justified to elucidate the explicit role of LRIG1 in the oncogenesis of RCC.
|
14520461 |
2003 |
|
Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further studies are justified to elucidate the explicit role of LRIG1 in the oncogenesis of RCC.
|
14520461 |
2003 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT--PCR and immunohistochemical analysis.
|
14520461 |
2003 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
None of these genes, except LRIG1, showed expression in any of the tested tissues (including normal adult and fetal kidney, sporadic kidney tumours and tumour samples from the proband's family).
|
15016767 |
2004 |
|
Kidney Neoplasm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
None of these genes, except LRIG1, showed expression in any of the tested tissues (including normal adult and fetal kidney, sporadic kidney tumours and tumour samples from the proband's family).
|
15016767 |
2004 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased LRIG1 copy number was associated with increased levels of LRIG1 mRNA (two of three tumours) and protein (four of four tumours) in the tumours compared to matched non-neoplastic breast tissue, as assessed by RT-PCR and western blot analysis.
|
16168117 |
2005 |
|
Malignant neoplasm of breast
|
0.060 |
Biomarker
|
disease |
BEFREE |
The molecular function of LRIG1 as a negative regulator of ERBB receptors questions the biological significance of increased LRIG1 copy number in breast cancer.
|
16168117 |
2005 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
The molecular function of LRIG1 as a negative regulator of ERBB receptors questions the biological significance of increased LRIG1 copy number in breast cancer.
|
16168117 |
2005 |
|
Mammary Neoplasms
|
0.030 |
GeneticVariation
|
group |
LHGDN |
Increased copy number at 3p14 in breast cancer.
|
16168117 |
2005 |
|
Glioma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
LRIG1-3 mRNA was detected in all human glioma cell lines and matched glioma samples, with large differences in the expression levels.
|
16532360 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LRIG1 might act as a tumour-suppressor gene, participating in negative feedback control of EGFR expression, which inhibits bladder cancer cells from growth, migration and invasion.
|
16978290 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we evaluated the mRNA expression level of LRIG1-3 in human glioma cell lines and control-matched glioma tissues, characterized the sub-cellular localization of an LRIG3-GFP fusion protein, and analyzed the relationship between sub-cellular localization of LRIG1-3 and clinical parameters in 404 astrocytic tumors by immunohistochemistry.
|
16532360 |
2006 |
|
Tumor Cell Invasion
|
0.080 |
AlteredExpression
|
phenotype |
BEFREE |
LRIG1 might act as a tumour-suppressor gene, participating in negative feedback control of EGFR expression, which inhibits bladder cancer cells from growth, migration and invasion.
|
16978290 |
2006 |
|
Malignant neoplasm of urinary bladder
|
0.040 |
Biomarker
|
disease |
BEFREE |
LRIG1, a candidate tumour-suppressor gene in human bladder cancer cell line BIU87.
|
16978290 |
2006 |
|
Bladder Neoplasm
|
0.040 |
Biomarker
|
disease |
BEFREE |
LRIG1, a candidate tumour-suppressor gene in human bladder cancer cell line BIU87.
|
16978290 |
2006 |
|
Carcinoma of bladder
|
0.040 |
Biomarker
|
disease |
BEFREE |
LRIG1, a candidate tumour-suppressor gene in human bladder cancer cell line BIU87.
|
16978290 |
2006 |
|
Colorectal Carcinoma
|
0.140 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, there was a great heterogeneity in the expression of the LRIG1 protein in colorectal cancer, which was not related to gene dosage of the LRIG1 gene.
|
17851870 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the present study the expression of LRIG1 (leucine rich repeats and immunoglobin-like domains 1) and its relation to EGFR (epidermal growth factor receptor) was examined in tumour samples and adjacent non-neoplastic tissues from 30 patients with colorectal cancer.
|
17851870 |
2007 |
|
Malignant neoplasm of breast
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of LRIG1 destabilizes endogenous Met receptor in breast cancer cells and impairs their ability to respond to HGF.
|
17178829 |
2007 |
|
Breast Carcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of LRIG1 destabilizes endogenous Met receptor in breast cancer cells and impairs their ability to respond to HGF.
|
17178829 |
2007 |